Cast lipid implants for controlled drug delivery: Importance of the tempering conditions

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3471-3481

  Kreye, Frauke ^a,b   Siepmann, Florence ^a,b   Zimmer, Anna ^a,b   Willart, Jean Francois ^a   Descamps, Marc ^a   Siepmann, Juergen ^a,b  

^a UNIV LILLE   (France)

^b Faculté de Médecine H Warembourg   (France)

Author keywords

Controlled release; Drug transport; Implant; Lipid; Mathematical modeling; Tempering; Thermal analysis

Indexed keywords

COTTON SEED OIL; DYNASAN 120; HYDROGENATED VEGETABLE OIL; LIPID; PROPRANOLOL; SOYBEAN OIL; STEREOTEX NF; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DIFFUSION; DRUG DELIVERY SYSTEM; HEAT TREATMENT; IMPLANT; MASS; MORPHOLOGY; PARTICLE SIZE; POROSITY; SOLID STATE; TEMPERATURE DEPENDENCE; WATER TRANSPORT;

EID: 79958819186     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22574     Document Type: Article

References (42)

1. Wang P. 1999. Implant preparations containing bioactive macromolecule for sustained delivery. Patent US5939380.
2. Yamagata Y, Iga K, Ogawa Y. 2000. Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids. J Control Release 63:319-329.
3. Mohl S, Winter G. 2004. Continuous release of rh-interferon α-2a from triglyceride matrices. J Control Release 97:67-78.
4. Lee HY, Kim SK, Kim JS, Jung YH, Kim JI, Seo YM, Lee JS, Seol EY, Chang SG, Choi HI. 2005. Protein-containing lipid implant for sustained delivery and its preparation method. Patent WO 2005102284.
5. Guse C, Koennings S, Kreye F, Siepmann F, Goepferich A, Siepmann J. 2006. Drug release from lipid-based implants: Elucidation of the underlying mass transport mechanisms. Int J Pharm 314:137-144.
6. Koennings S, Sapin A, Blunk T, Menei P, Goepferich A. 2007. Towards controlled release of BDNF-Manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. J Control Release 119:163-172.
7. Kreye F, Siepmann F, Siepmann J. 2008. Lipid implants as drug delivery systems. Expert Opin Drug Deliv 5:291-307.
8. Kreye F, Siepmann F, Siepmann J. 2011. Drug release mechanisms of compressed lipid implants. Int J Pharm 404:27-35.
9. Ravivarapu HB, Burton K, DeLuca PP. 2000. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 50:263-270.
10. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. 2005. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57:391-410.
11. Lucke A, Goepferich A. 2003. Acylation of peptides by lactic acid solutions. Eur J Pharm Biopharm 55:27-33.
12. Estey T, Kang J, Schwendeman SP, Carpenter JF. 2006. BSA degradation under acidic conditions: A model for protein instability during release from PLGA delivery systems. J Pharm Sci 95:1626-1639.
13. Wang PY. 1989. Lipids as excipient in sustained release insulin implants. Int J Pharm 54:223-230.
14. Allababidi S, Shah JC. 1998. Efficacy and pharmacokinetics of site-specific cefazolin delivery using biodegradable implants in the prevention of post-operative wound infections. Pharm Res 15:325-333.
15. Chilukuri D, Shah JC. 2005. Local delivery of vancomycin for the prophylaxis of prosthetic device-related infections. Pharm Res 22:563-572.
16. Guse C, Koennings S, Maschke A, Hacker M, Becker C, Schreiner S, Blunk T, Spruss T, Goepferich A. 2006. Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. Int J Pharm 314:153-160.
17. Schwab M, Kessler B, Wolf E, Jordan G, Mohl S, Winter G. 2008. Correlation of in vivo and in vitro release data for rh-INFα lipid implants. Eur J Pharm Biopharm 70:690-694.
18. Herrmann S, Winter G, Mohl S, Siepmann F, Siepmann J. 2007. Mechanisms controlling protein release from lipidic implants: Effects of PEG addition. J Control Release 118:161-168.
19. Kreye F, Siepmann F, Zimmer A, Descamps M, Siepmann J. Controlled release implants based on lipid blends. Eur J Pharm Sci, in press.
20. Kreye F, Siepmann F, Siepmann J. Drug release mechanisms of molten lipid implants. Eur J Pharm Biopharm, in press.
21. Knepp V, Muchnik A, Oldmark S, Kalashnikova L. 1998. Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures. Pharm Res 15:1090-1095.
22. Klibanov AM. 2001. Improving enzymes by using them in organic solvents. Nature 409:241-246.
23. Pongjanyakul T, Medlicott NJ, Tucker IG. 2004. Melted glyceryl palmitostearate (GPS) pellets for protein delivery. Int J Pharm 271:53-62.
24. Chapman D. 1962. The polymorphism of glycerides. Chem Rev 62:433-456.
25. Hagemann JW. 1988. Thermal behavior and polymorphism of acylglycerides. In: Crystallization and polymorphism of fats and fatty acids; Garti N, Sato K, Eds. New York: Marcel Dekker; pp 9-97.
26. Sato K. 2001. Crystallization behaviour of fats and lipids-A review. Chem Eng Sci 56:2255-2265.
27. Himawan C, Starov VM, Stapley AGF. 2006. Thermodynamic and kinetic aspects of fat crystallization. Adv Colloid Interface Sci 122:3-33.
28. San Vicente A, Hernandez RM, Gascon AR, Calvo MB, Pedraz JL. 2000. Effect of aging on the release of salbutamol sulfate from lipid matrices. Int J Pharm 2008:13-21.
29. Sutananta W, Craig DQM, Newton JM. 1994. An investigation into the effect of preparation conditions on the structure and mechanical properties of pharmaceutical glyceride bases. Int J Pharm 110:75-91.
30. Rodriguez-Hornedo N, Murphy D. 1999. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 88:651-660.
31. Heinz A, Savolainen M, Rades T, Strachan CJ. 2007. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. Eur J Pharm Sci 32:182-192.
32. Choy YW, Khan N, Yuen KH. 2005. Significance of lipid matrix aging on in vitro release and in vivo bioavailability. Int J Pharm 299:55-64.
33. Khan N, Craig DQM. 2004. Role of blooming in determining the storage stability of lipid-based dosage forms. J Pharm Sci 93:2962-2971.
34. Windbergs M, Strachan CJ, Kleinebudde P. 2009. Investigating the principles of recrystallization from glyceride melts. AAPS PharmSciTech 10:doi:10.1208/s12249-009-9311-5.
35. Siepmann J, Siepmann F. 2008. Mathematical modeling of drug delivery. Int J Pharm 364:328-343.
36. Siepmann J, Goepferich A. 2001. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 48:229-247.
37. Siepmann J, Peppas NA. 2001. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 48:139-157.
38. Ghotra BS, Dyal SD, Narine SS. 2002. Lipid shortenings: A review. Food Res Int 35:1015-1048.
39. Rousseau D, Hodge SM, Nickerson MT, Paulson AT. 2005. Regulating the beta-prime to beta polymorphic transition in food fats. J Am Oil Chem Soc 82:7-12.
40. Vergnaud J. 1993. Controlled drug release of oral dosage forms. Chichester, UK: Ellis Horwood Limited.
41. Hoerr CW. 1960. Morphology of fats, oils, and shortenings. J Am Oil Chem Soc 37:539-546.
42. deMan L, de Man JM, Blackman B. 1989. Polymorphic behavior of some fully hydrogenated oils and their mixtures with liquid oil. J Am Oil Chem Soc 66:1777-1780.